RRR-α-tocopheryl succinate induction of DNA synthesis arrest of human MDA-MB-435 cells involves TGF-β-independent activation of p21Waf1/Cip1

Nutrition and Cancer

Volumn 43, Issue 2, 2002, Pages 227-236

  Yu, Weiping ^a   Sanders, Bob G ^a   Kline, Kimberly ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; NEUTRALIZING ANTIBODY; PROTEIN P21; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL STRAIN; CELL STRAIN MDA MB 435; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; GENE ACTIVATION; GENE CONTROL; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REPORTER GENE; UPREGULATION;

EID: 0036968662     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/S15327914NC432_13     Document Type: Article

References (53)

1. Kline K, Yu W, and Sanders BG: Vitamin E: mechanisms of action as tumor cell growth inhibitors. J Nutr 131, 161S-163S, 2001.
2. Kline K, Yu W, and Sanders BG: Vitamin E: mechanisms of action as tumor cell growth inhibitors. In Proceedings of the International Conference on Nutrition and Cancer, Prasad KN and Cole WC (eds). Amsterdam: IOS, 1998, pp 37-53.
3. Prasad KN and Edwards-Prasad J: Vitamin E and cancer prevention: recent advances and future potentials. J Am Coll Nutr 11, 487-500, 1992.
4. Malafa MP and Neitzel LT: Vitamin E succinate promotes breast cancer tumor dormancy. J Surg Res 93, 163-170, 2000.
5. Neuzil J, Weber T, Gellert N, and Weber C: Selective cancer cell killing by α-tocopheryl succinate. Br J Cancer 84, 87-89, 2000.
6. Neuzil J, Weber T, Schroder A, Lu M, Ostermann G, et al.: Induction of cancer cell apoptosis by α-tocopheryl succinate: molecular pathways and structural requirements. FASEB J 15, 403-415, 2001.
7. Charpentier A, Groves S, Simmons-Menchaca M, Turley J, Zhao B, et al.: RRR-α-tocopheryl succinate inhibits proliferation and enhances secretion of transforming growth factor-β (TGF-β) by human breast cancer cells. Nutr Cancer 19, 225-239, 1993.
8. Charpentier A, Simmons-Menchaca M, Yu W, Zhao B, Qian M, et al.: RRR-α-tocopheryl succinate enhances TGF-β1, -β2, and -β3 and TGF-βR-II expression by human MDA-MB-435 breast cancer cells. Nutr Cancer 26, 237-250, 1996.
9. Yu W, Heim K, Qian M, Simmons-Menchaca M, Sanders BG, et al.: Evidence for role of transforming growth factor-β in RRR-α-tocopheryl succinate-induced apoptosis of human MDA-MB-435 breast cancer cells. Nutr Cancer 27, 267-278, 1997.
10. Yu W, Simmons-Menchaca M, You H, Brown P, Birrer MJ, et al.: RRR-α-tocopheryl succinate induction of prolonged activation of c-Jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. Mol Carcinog 22, 247-257, 1998.
11. r 43,000 Fas in VES-triggered apoptosis. Cancer Res 59, 953-961, 1999.
12. Yu W, Liao QY, Hantash FM, Sanders BG, and Kline K: Activation of extracellular signal-regulated kinase and c-Jun-NH2-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-α-tocopheryl succinate-induced apoptosis of human breast cancer cells. Cancer Res 61, 6569-6576, 2001.
13. You H, Yu W, Sanders BG, and Kline K: RRR-α-tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation. Cell Growth Differ 12, 471-480, 2001.
14. Djuric Z, Heilbrun LK, Lababidi S, Everett-Bauer CK, and Fariss MW: rowth inhibition of MCF-7 and MCF-10A human breast cells by α-tocopheryl hemisuccinate, cholesteryl hemisuccinate and their ether analogs. Cancer Lett 111, 133-139, 1997.
15. Turley JM, Fu T, Ruscetti FW, Mikovits JA, Bertolette DC, et al.: Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Res 57, 881-890, 1997.
16. Turley JM, Ruscetti FW, Kim S-J, Fu T, and Gou FV: Vitamin E succinate inhibits proliferation of BT-20 human breast cancer cells: increased binding of cyclin A negatively regulates E2F transactivation activity. Cancer Res 57, 2668-2675, 1997.
17. Pussinen PJ, Lindner H, Glatter O, Reicher H, Kostner GM, et al.: Lipoprotein-associated α-tocopheryl succinate inhibits cell growth and induced apoptosis in human MCF-7 and HBL-100 breast cancer cells. Biochim Biophys Acta 1485, 129-144, 2000.
18. WAF1 expression and growth inhibition by transforming growth factor-β involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 57, 3929-3934, 1997.
19. El-Deiry WS: p21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol 227, 121-137, 1998.
20. WAF1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression. Cancer Res 60, 156-163, 2000.
21. WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 60, 679-684, 2000.
22. Gartel AL, Serfas MS, and Tyner A: p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213, 138-149, 1996.
23. 1 phase and cell cycle regulation by TGF-β. Adv Cancer Res 71, 165-207, 1997.
24. WAF1/cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc NatlAcadSci USA 95, 67334738, 1998.
25. Massague J: TGF-β signal transduction. Annu Rev Biochem 67, 753-791, 1998.
26. Massague J and Chen Y-G: Controlling TGF-β signaling. Genes Dev 14, 627-644, 2000.
27. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, et al.: TGF-β receptor-mediated signalling though Smad2, Smad3 and Smad4. EMBO J 16, 5353-5362, 1997.
28. Shibuya H, Yamaguchi K, Shirakabe K, Tonegawa A, Gotoh Y, et al.: TAB1: an activator of the TAK1 MAPKKK in TGF-β signal transduction. Science 272, 1179-1182, 1996.
29. Atfi A, Djelloul S, Chastre E, Davis R, and Gespach C: Evidence for a role of Rho-like GTPases and stress-activated kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor β-mediated signaling. J Biol Chem 272, 1429-1431, 1997.
30. Tibbles LA and Woodgett JR: The stress-activated protein kinase pathways. Cell Mol Life Sci 55, 1230-1254, 1999.
31. Mulder K: Role of Ras and Mapks in TGFβ signaling. Cytokine Growth Factor Rev 11, 23-35, 2000.
32. Price JE, Polyzos A, Zhang RD, and Daniels LM: Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50, 717-721, 1990.
33. Klotz DM, Castles CG, Fuqua SAW, Spriggs LL, and Hill SM: Differential expression of wild-type and variant ER mRNAs by stocks of MCF-7 breast cancer cells may account for differences in estrogen responsiveness. Biochem Biophys Res Commun 210, 609-615, 1995.
34. Qian M, Kralova J, Yu W, Bose HR, Dvorak M, et al.: c-Jun involvement in vitamin E succinate-induced apoptosis of reticuloendotheliosis virus-transformed avian lymphoid cells. Oncogene 15, 223-230, 1997.
35. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, et al.: Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1, 611-617, 1998.
36. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, et al.: TGF-β signals through a heterometric protein kinase receptor complex. Cell 71, 1003-1014, 1992.
37. Datto MB, Yu Y, and Wang X-F: Functional analysis of the transforming growth factor β responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 270, 28623-28628, 1995.
38. de Caestecker MP, Piek E, and Roberts AB: Role of transforming growth factor-β signaling in cancer. JNCI 92, 1388-1402, 2000.
39. Sherr CJ: The Pezcoller Lecture: cancer cell cycles revisited. Cancer Res 60, 3689-3695, 2000.
40. 1 cyclin-dependent kinases. Genes Dev 9, 1149-1163, 1995.
41. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, and Stanbridge EJ: Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6, 1791-1797, 1991.
42. Nielsen LL, Dell J, Maxwell E, Armstrong L, Maneval D, et al.: Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 4, 129-138, 1997.
43. Waf1 promoter region. Cancer Res 60, 3290-3298, 2000.
44. Darnell JE Jr: STATs and gene regulation. Science 277, 1630-1635, 1997.
45. p21WAF/CIP1 gene. Exp Cell Res 246, 280-289, 1999.
46. Liu Y, Zhong X, Li W, Brattain MG, and Banerji S: The role of SP1 in the differential expression of TGFβ receptor type II in human breast cancer MCF-7 cells. J Biol Chem 275, 12231-12236, 2000.
47. Kim S-J, Im Y-H, Markowitz SD, and Bang Y-J: Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis. Cytokine Growth Factor Rev 11, 159-168, 2000.
48. Hartsoug ME and Mulder KM: Transforming growth factor-β signaling in epithelial cells. Pharmacol Ther 75, 21-41, 1997.
49. Wakefield LM, Smith DM, Masui T, Harris CC, and Sporn MB: Distribution and modulation of the cellular receptor for transforming growth factor-β. J Cell Biol 105, 965-975, 1987.
50. Fan D, Price J, Schackert H, Seid C, Wilmanns C, et al.: Antiproliferative activity of liposome-encapsulated transforming growth factor-β against MDA-MB-435 human breast carcinoma cells. Cancer Commun 1, 337-343, 1989.
51. Frey RS and Mulder KM: Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/jun-N-terminal kinase activation by transforming growth factor β in the negative growth control of breast cancer cells. Cancer Res 57, 628-633, 1997.
52. Zugmaier G, Ennis BW, Deschauer B, Katz D, Knabbe C, et al.: Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 141, 353-361, 1989.
53. Spore MB and Roberts AB: Peptide growth factors are multifunctional. Nature 332, 217-219, 1988.